Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Cervical Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
39 drugs · 148 active trials
4 drugs · 53 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dostarlimab | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Jun 28, 2019 |
| Ipatasertib | Phase 2 | Phase 2 | 3 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Everolimus | Phase 2 | Phase 2 | 2 | 0 | 0 | 5 | 0 | — | — | 2009-12 |
| Metformin | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | 2012-12 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | May 31, 2010 |
| Adebrelimab | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | 2024-01 |
| Capivasertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Dec 1, 2010 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Dec 17, 2012 |
| Disitamab Vedotin | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jan 11, 2024 |
| Megestrol | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Mar 31, 2023 |
| Sapanisertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | May 20, 2014 |
| Cetuximab | Phase 2 | Phase 2 | 1 | 1 | 0 | 11 | 0 | — | — | 2004-09 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 10 | 0 | — | — | 1999-11 |
| Sintilimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Jul 31, 2019 |
| Tremelimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Dec 19, 2013 |
| Avelumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Sep 1, 2017 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2009-12 |
| Lifileucel | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 22, 2017 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2007-01 |
| Cabozantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | May 8, 2013 |
| Fulvestrant | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 31, 2021 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ruxolitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 14, 2016 |
| Trametinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2013-10 |
| Tretinoin | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 1999-01 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Alemtuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-11 |
| Anti-VEGF Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 24, 2026 |
| Avutometinib And Defactinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 6, 2023 |
| Belzutifan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 20, 2024 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Datopotamab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 1, 2023 |
| Ribociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 18, 2017 |
| Sirolimus | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | 2026-11 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 27, 2017 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tazemetostat | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 1, 2019 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.